BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND CBFB, PEBP2B, 865, ENSG00000067955, Q13951 AND Treatment
15 results:

  • 1. Therapy-related acute myeloid leukemia with
    Yang X; Liu Q; Zhang R; Yang X; Wang L; Zhang Z; Li Y; Lin L
    Indian J Pathol Microbiol; 2023; 66(4):865-867. PubMed ID: 38084551
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A preoperative nomogram incorporating CT to predict the probability of ovarian clear cell carcinoma.
    Horvat N; Causa Andrieu P; Meier A; Ji X; Lakhman Y; Soslow R; Allison D; Gangai N; Rodriguez L; Kattan MW; Chi DS; Hricak H
    Gynecol Oncol; 2023 Sep; 176():90-97. PubMed ID: 37478617
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Germline cancer Gene Expression Quantitative Trait Loci Are Associated with Local and Global Tumor Mutations.
    Liu Y; Gusev A; Kraft P
    Cancer Res; 2023 Apr; 83(8):1191-1202. PubMed ID: 36745477
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Who are the long-term survivors of recurrent ovarian carcinoma?: a retrospective analysis of a multicenter study.
    Yoshihara M; Mogi K; Kitami K; Uno K; Iyoshi S; Tano S; Fujimoto H; Miyamoto E; Yoshikawa N; Emoto R; Matsui S; Kajiyama H
    Int J Clin Oncol; 2022 Oct; 27(10):1660-1668. PubMed ID: 35906336
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.
    Atwal A; Snowsill T; Dandy MC; Krum T; Newton C; Evans DG; Crosbie EJ; Ryan NAJ
    Int J Cancer; 2022 Nov; 151(9):1626-1639. PubMed ID: 35792468
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following treatment of Primary Epithelial ovarian cancer in the United States.
    Penn CA; Wong MS; Walsh CS
    JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.
    Liu J; Prager-van der Smissen WJC; Collée JM; Bolla MK; Wang Q; Michailidou K; Dennis J; Ahearn TU; Aittomäki K; Ambrosone CB; Andrulis IL; Anton-Culver H; Antonenkova NN; Arndt V; Arnold N; Aronson KJ; Augustinsson A; Auvinen P; Becher H; Beckmann MW; Behrens S; Bermisheva M; Bernstein L; Bogdanova NV; Bogdanova-Markov N; Bojesen SE; Brauch H; Brenner H; Briceno I; Brucker SY; Brüning T; Burwinkel B; Cai Q; Cai H; Campa D; Canzian F; Castelao JE; Chang-Claude J; Chanock SJ; Choi JY; Christiaens M; Clarke CL; ; Couch FJ; Czene K; Daly MB; Devilee P; Dos-Santos-Silva I; Dwek M; Eccles DM; Eliassen AH; Fasching PA; Figueroa J; Flyger H; Fritschi L; Gago-Dominguez M; Gapstur SM; García-Closas M; García-Sáenz JA; Gaudet MM; Giles GG; Goldberg MS; Goldgar DE; Guénel P; Haiman CA; Håkansson N; Hall P; Harrington PA; Hart SN; Hartman M; Hillemanns P; Hopper JL; Hou MF; Hunter DJ; Huo D; ; Ito H; Iwasaki M; Jakimovska M; Jakubowska A; John EM; Kaaks R; Kang D; Keeman R; Khusnutdinova E; Kim SW; Kraft P; Kristensen VN; Kurian AW; Le Marchand L; Li J; Lindblom A; Lophatananon A; Luben RN; Lubiński J; Mannermaa A; Manoochehri M; Manoukian S; Margolin S; Mariapun S; Matsuo K; Maurer T; Mavroudis D; Meindl A; Menon U; Milne RL; Muir K; Mulligan AM; Neuhausen SL; Nevanlinna H; Offit K; Olopade OI; Olson JE; Olsson H; Orr N; Park SK; Peterlongo P; Peto J; Plaseska-Karanfilska D; Presneau N; Rack B; Rau-Murthy R; Rennert G; Rennert HS; Rhenius V; Romero A; Ruebner M; Saloustros E; Schmutzler RK; Schneeweiss A; Scott C; Shah M; Shen CY; Shu XO; Simard J; Sohn C; Southey MC; Spinelli JJ; Tamimi RM; Tapper WJ; Teo SH; Terry MB; Torres D; Truong T; Untch M; Vachon CM; van Asperen CJ; Wolk A; Yamaji T; Zheng W; Ziogas A; Ziv E; Torres-Mejía G; Dörk T; Swerdlow AJ; Hamann U; Schmidt MK; Dunning AM; Pharoah PDP; Easton DF; Hooning MJ; Martens JWM; Hollestelle A
    Sci Rep; 2020 Jun; 10(1):9688. PubMed ID: 32546843
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Assessment of diagnostic utility of multivariate diagnostic models in differential diagnosis of ovarian tumors.
    Horała A; Swiatly A; Lorek J; Kokot ZJ; Matysiak J; Nowak-Markwitz E
    Ginekol Pol; 2018; 89(10):568-572. PubMed ID: 30393846
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California.
    Long B; Chang J; Ziogas A; Tewari KS; Anton-Culver H; Bristow RE
    Am J Obstet Gynecol; 2015 Apr; 212(4):468.e1-9. PubMed ID: 25448522
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.
    Raja FA; Counsell N; Colombo N; Pfisterer J; du Bois A; Parmar MK; Vergote IB; Gonzalez-Martin A; Alberts DS; Plante M; Torri V; Ledermann JA
    Ann Oncol; 2013 Dec; 24(12):3028-34. PubMed ID: 24190964
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Prevalence and prognostic impact of lymphadenectomy and lymph node metastasis in clinically early-stage ovarian clear cell carcinoma.
    Mahdi H; Moslemi-Kebria M; Levinson KL; Gojayev A; Lockhart D; Ali-Fehmi R; Munkarah AR
    Int J Gynecol Cancer; 2013 Sep; 23(7):1226-30. PubMed ID: 23736258
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials.
    Ye Q; Chen HL
    Arch Gynecol Obstet; 2013 Sep; 288(3):655-66. PubMed ID: 23543268
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Expression of tumor suppressor gene ING4 in ovarian carcinoma is correlated with microvessel density.
    Liu Y; Yu L; Wang Y; Zhang Y; Wang Y; Zhang G
    J Cancer Res Clin Oncol; 2012 Apr; 138(4):647-55. PubMed ID: 22228137
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Residual tumor after the salvage surgery is the major risk factors for primary treatment failure in malignant ovarian germ cell tumors: a retrospective study of single institution.
    Lee CW; Song MJ; Park ST; Ki EY; Lee SJ; Lee KH; Ryu KS; Park JS; Hur SY
    World J Surg Oncol; 2011 Oct; 9():123. PubMed ID: 21988930
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The significance of duration of chemotherapy interruptions due to interval surgery in ovarian cancer patients treated with neoadjuvant chemotherapy.
    Le T; Fathi KA; Hopkins L; Faught W; Fung-Kee-Fung M
    J Obstet Gynaecol Can; 2009 Feb; 31(2):161-6. PubMed ID: 19327216
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.